Bolt Biotherapeutics
Price & Volume
Stats
See moreOpen | $0.39 |
Previous Close | $0.40 |
Day Range | $0.38-$0.39 |
52W Range | $0.38-$1.39 |
Market Cap | $15.3M |
Shares Short | 24,333 |
Financials
See moreRevenue (12 Mos) | $7.6M |
Revenue Growth (YoY) | -100% |
Gross Profit (12 Mos) | -$49.7M |
Diluted EPS | -$1.65 |
News
See moreYahoo Finance • 9 days ago
Bolt Biotherapeutics to Present Data from Phase 1 Dose-Escalation Clinical Study of BDC-3042 at AACR Annual Meeting 2025
Yahoo Finance • 10 days ago
Bolt Biotherapeutics Reports Fourth Quarter and Full-Year 2024 Financial Results and Provides Business Update
Yahoo Finance • last year
Bolt Biotherapeutics Enrolls First Patient in Phase 2 Clinical Study Evaluating BDC-1001 in Patients with HER2-Positive Breast Cancer Previously Treated with Enhertu®
Yahoo Finance • last year
Bolt Biotherapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update
About
CEO | Mr. William P. Quinn |
CFO | Mr. William P. Quinn |
Address | 900 Chesapeake Drive, Redwood City, CA, United States, 94063 |
Sector | Healthcare |
Industry | Biotechnology |
Full-Time Employees | 52 |
